Friend Zhijian Biotechnology: Clinical data from two studies on the M701 will be presented at the 2026 ASCO Annual Meeting.

Youzhijiubio announced that the results of two clinical studies of the core national category 1 innovative drug M701 "CD3/EpCAM bispecific antibody" will be presented at the 2026 American Clinical Oncology Society Annual Meeting: Phase III registered clinical study for malignant ascites and Phase II clinical study for malignant pleural effusion related to non-small cell lung cancer.